# Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

> **NCT04663347** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 543 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- **DRUG:** rituximab and lenalidomide
- **DRUG:** rituximab and bendamustine
- **DRUG:** rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin
- **DRUG:** gemcitabine and oxaliplatin
- **BIOLOGICAL:** Epcoritamab
- **DRUG:** rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone
- **DRUG:** Lenalidomide
- **DRUG:** rituximab, ifosfamide, carboplatin, and etoposide phosphate
- **BIOLOGICAL:** Epcoritamab
- **BIOLOGICAL:** Epcoritamab
- **BIOLOGICAL:** Epcoritamab
- **BIOLOGICAL:** Epcoritamab
- **BIOLOGICAL:** Epcoritamab
- **BIOLOGICAL:** Epcoritamab
- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Rituximab and Lenalidomide
- **BIOLOGICAL:** Epcoritamab

## Key facts

- **NCT ID:** NCT04663347
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-03
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 543 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04663347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04663347, "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04663347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*